For population groups known to experience excess disease-related morbidity, and mortality it was believed that the ability to use genetics to predict, prevent, detect, and more effectively treat disease held tremendous promise. Ten years after completion of the map, HGP leaders report several accomplishments of the HGP. They report the identification of approximately 1,800 disease genes [4, 5], the development of more than 2,000 genetic tests for various human diseases/conditions [6], and the development and ongoing testing of more than 350 biotechnology-based genetic products [4]. Yet, in a more subdued voice, they note that the anticipated clinical benefit from the HGP has yet to unfold [3].
